Stock 1530 3SBIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

News 3SBio Inc.

Equities

1530

KYG8875G1029

Delayed Hong Kong S.E.
Other stock markets
 11:59:44 2024-04-18 pm EDT 		5-day change 1st Jan Change
5.56 HKD -1.77% Intraday chart for 3SBio Inc. -6.55% -26.06%
Apr. 15 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia MT
Apr. 12 3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia
MT
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication
CI
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023.
CI
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates
MT
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024
CI
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product
MT
Mandi Foam of 3SBio Inc. Approves for Market Launch
CI
Venus Medtech Names Former 3SBio Finance Chief as CFO
MT
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China
MT
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates
MT
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced
PR
3SBio : 2023 Interim Results Presentation
PU
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
3SBio Hires Former JPMorgan Exec as CFO
MT
3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer
CI
3SBio Rolls Out Pruritus Medication in China
MT
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market
CI
3SBio Inc.'s Equity Buyback announced on July 15, 2022, has expired.
CI
3SBio Enrolls First Patient in Phase 3 Trial of Thrombocytopenia Treatment
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1530 Stock
  4. News 3SBio Inc.